Inhibikase Therapeutics (IKT)
(Delayed Data from NSDQ)
$1.39 USD
+0.05 (3.73%)
Updated Sep 9, 2024 03:59 PM ET
After-Market: $1.39 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
IKT 1.39 +0.05(3.73%)
Will IKT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IKT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IKT
Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now
New Strong Buy Stocks for February 13th
IKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for February 8th
New Strong Buy Stocks for February 8th
New Strong Buy Stocks for February 6th
Other News for IKT
Inhibikase Therapeutics Inc (IKT) Q2 2024 Earnings Call Transcript Highlights: Improved ...
Inhibikase Therapeutics GAAP EPS of -$0.66 beats by $0.01
Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024